ArticleScientific reports2025

Efficacy and toxicity of post-neoadjuvant trastuzumab emtansine in HER2-positive breast cancer patients treated at Institut Curie Hospitals.

Alexandre De Moura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.